The Robert Jones and Agnes Hunt Orthopaedic Hospital, Gobowen, Oswestry, SY10 7AG, UK.
J Orthop Surg Res. 2022 Apr 18;17(1):241. doi: 10.1186/s13018-022-03124-2.
The purpose of this study was to evaluate the efficacy of intrathecal morphine (ITM) in combination with bupivacaine as pre-emptive analgesia in patients undergoing posterior lumbar fusion surgery. This is in comparison with traditional opioid analgesics such as intravenous (IV) morphine.
Two groups were identified retrospectively. The first (ITM group) included patients who had general anaesthesia (GA) with low-dose spinal anaesthesia prior to induction using 1-4 mls of 0.25% bupivacaine and 0.2 mg ITM. 1 ml of 0.25% bupivacaine was administered per hour of predicted surgery time, up to a maximum of 4 ml. The insertion level for the spinal anaesthetic corresponded to the spinal level of the iliac crest line and the level at which the spinal cord terminated. The control group had GA without any spinal anaesthesia. Patients were instead administered opioid analgesia in the form of IV morphine or diamorphine. The primary outcome was the consumption of opioids administered intraoperatively and in recovery, and over the first 48 h following discharge from the post-anaesthesia care unit (PACU). Total opioid dose was measured, and a morphine equivalent dose was calculated. Secondary outcomes included visual analogue scale (VAS) pain scores in recovery and at day two postoperatively, and the length of stay in hospital.
For the ITM group, the median total amount of IV morphine equivalent administered intraoperatively and in recovery, was 0 mg versus 17 mg. The median total amount morphine equivalent, administered over the first 48 h following discharge from PACU was 20 mg versus 80 mg. Both are in comparison with the control group. The median length of stay was over 1 day less and the median VAS for pain in recovery was 6 points lower. No evidence was found for a difference in the worst VAS for pain at day two postoperatively.
ITM in combination with bupivacaine results in a significantly decreased use of perioperative opioids. In addition, length of hospital stay is reduced and so too is patient perceived pain intensity. Trial registration The study was approved by the ethics committee at The Robert Jones and Agnes Hunt Orthopaedic Hospital as a service improvement project (Approval no. 1617_004).
本研究旨在评估鞘内注射吗啡(ITM)联合布比卡因作为后路腰椎融合术患者预防性镇痛的疗效。与传统的阿片类镇痛药(如静脉注射(IV)吗啡)相比。
回顾性分析两组患者。第一组(ITM 组)包括接受全身麻醉(GA)并在诱导前使用 1-4ml 0.25%布比卡因和 0.2mg ITM 进行低剂量脊髓麻醉的患者。每小时预测手术时间给予 1ml 0.25%布比卡因,最大剂量为 4ml。脊髓麻醉的插入水平与髂嵴线的脊柱水平和脊髓终止的水平相对应。对照组在没有任何脊髓麻醉的情况下接受 GA。患者以静脉注射吗啡或二氢吗啡酮的形式给予阿片类镇痛药。主要结局是术中及术后恢复期间以及离开麻醉后护理单元(PACU)后 48 小时内使用的阿片类药物的消耗量。测量总阿片类药物剂量,并计算吗啡等效剂量。次要结局包括术后恢复和术后第二天的视觉模拟评分(VAS)疼痛评分,以及住院时间。
对于 ITM 组,术中及术后恢复期间给予 IV 吗啡等效物的中位数总量为 0mg 与 17mg。从 PACU 出院后 48 小时内给予的吗啡等效物中位数总量为 20mg 与 80mg。与对照组相比。中位住院时间减少了 1 天以上,术后恢复时的中位 VAS 疼痛评分降低了 6 分。在术后第二天的最差 VAS 疼痛方面没有发现差异的证据。
ITM 联合布比卡因可显著减少围手术期阿片类药物的使用。此外,还降低了住院时间和患者感知的疼痛强度。试验注册本研究作为服务改进项目经罗伯特·琼斯和艾格尼丝·亨特骨科医院伦理委员会批准(批准号 1617_004)。